British journal of cancer · 2001

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G

Аннотация

Skeletal metastases from thyroid cancer are poorly responsive to medical or radioiodine treatment. Bone destruction in skeletal metastases results from osteoclast-induced bone resorption. Therefore, a new approach in the therapy of bone metastases consists in using aminobisphosphonates, such as pamidronate, which are potent inhibitors of osteoclastic activity. In the present study, 10 thyroid cancer patients with painful osteolytic bone metastases were administered pamidronate (90 mg, as a 2 hour intravenous infusion) monthly for 12 consecutive cycles. Bone pain, quality of life, performance status, analgesic consumption and disease staging were evaluated before and during the trial. The patients who had been administered pamidronate showed a significant decrease in bone pain (P = 0.0052). Performance status improved nearly significantly (P = 0.051), while the quality of life showed a remarkable amelioration. However, no significant decrease in analgesic consumption was recorded. Partial radiographic response of bone lesions was observed in 2/10 patients. The side effects of pamidronate were mild and transient. In conclusion, monthly infusion of pamidronate is a well-tolerated treatment that induces significant relief from bone pain and improves the quality of life of thyroid cancer patients with symptomatic and osteolytic bone metastases.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Full Text

The Full Text of this article is available as a PDF (59.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Aparicio A., Gardner A., Tu Y., Savage A., Berenson J., Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998 Feb;12(2):220–229. doi: 10.1038/sj.leu.2400892.

Benford H. L., Frith J. C., Auriola S., Mönkkönen J., Rogers M. J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol. 1999 Jul;56(1):131–140. doi: 10.1124/mol.56.1.131.

Body J. J. Metastatic bone disease: clinical and therapeutic aspects. Bone. 1992;13 (Suppl 1):S57–S62. doi: 10.1016/s8756-3282(09)80011-2.

Cascinu S., Graziano F., Alessandroni P., Ligi M., Del Ferro E., Rossi D., Ficarelli R., Catalano G. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer. 1998 Mar;6(2):139–143. doi: 10.1007/s005200050148.

Cella D. F., Tulsky D. S., Gray G., Sarafian B., Linn E., Bonomi A., Silberman M., Yellen S. B., Winicour P., Brannon J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570–579. doi: 10.1200/JCO.1993.11.3.570.

Coleman R. E., Rubens R. D. Bone metastases and breast cancer. Cancer Treat Rev. 1985 Dec;12(4):251–270. doi: 10.1016/0305-7372(85)90008-8.

Coleman R. E., Woll P. J., Miles M., Scrivener W., Rubens R. D. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer. 1988 Nov;58(5):621–625. doi: 10.1038/bjc.1988.272.

Derenne S., Amiot M., Barillé S., Collette M., Robillard N., Berthaud P., Harousseau J. L., Bataille R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999 Dec;14(12):2048–2056. doi: 10.1359/jbmr.1999.14.12.2048.

Gillenwater A. M., Weber R. S. Thyroid carcinoma. Cancer Treat Res. 1997;90:149–169. doi: 10.1007/978-1-4615-6165-1_8.

Grebe S. K., Hay I. D. Follicular thyroid cancer. Endocrinol Metab Clin North Am. 1995 Dec;24(4):761–801.

Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f.

Lipton A., Glover D., Harvey H., Grabelsky S., Zelenakas K., Macerata R., Seaman J. Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol. 1994;5 (Suppl 7):S31–S35.

Lupoli G., Cascone E., Arlotta F., Vitale G., Celentano L., Salvatore M., Lombardi G. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer. 1996 Sep 1;78(5):1114–1118. doi: 10.1002/(SICI)1097-0142(19960901)78:5<1114::AID-CNCR23>3.0.CO;2-4.

Marcocci C., Pacini F., Elisei R., Schipani E., Ceccarelli C., Miccoli P., Arganini M., Pinchera A. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery. 1989 Dec;106(6):960–966.

Maxon H. R., 3rd, Smith H. S. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990 Sep;19(3):685–718.

Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.

Morton A. R., Cantrill J. A., Pillai G. V., McMahon A., Anderson D. C., Howell A. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ. 1988 Sep 24;297(6651):772–773. doi: 10.1136/bmj.297.6651.772.

Proye C. A., Dromer D. H., Carnaille B. M., Gontier A. J., Goropoulos A., Carpentier P., Lefebvre J., Decoulx M., Wemeau J. L., Fossati P. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg. 1992 Jul-Aug;16(4):640–646. doi: 10.1007/BF02067343.

Reszka A. A., Halasy-Nagy J. M., Masarachia P. J., Rodan G. A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem. 1999 Dec 3;274(49):34967–34973. doi: 10.1074/jbc.274.49.34967.

Schlumberger M. J. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998 Jan 29;338(5):297–306. doi: 10.1056/NEJM199801293380506.

Shipman C. M., Rogers M. J., Apperley J. F., Russell R. G., Croucher P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997 Sep;98(3):665–672. doi: 10.1046/j.1365-2141.1997.2713086.x.

Tong D., Gillick L., Hendrickson F. R. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982 Sep 1;50(5):893–899. doi: 10.1002/1097-0142(19820901)50:5<893::aid-cncr2820500515>3.0.co;2-y.

Tubiana M., Haddad E., Schlumberger M., Hill C., Rougier P., Sarrazin D. External radiotherapy in thyroid cancers. Cancer. 1985 May 1;55(9 Suppl):2062–2071. doi: 10.1002/1097-0142(19850501)55:9+<2062::aid-cncr2820551406>3.0.co;2-o.

Vitale G., Tagliaferri P., Caraglia M., Rampone E., Ciccarelli A., Bianco A. R., Abbruzzese A., Lupoli G. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2000 Mar;85(3):983–988. doi: 10.1210/jcem.85.3.6435.

van Beek E., Pieterman E., Cohen L., Löwik C., Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999 Feb 16;255(2):491–494. doi: 10.1006/bbrc.1999.0224.

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.

Ошибки и ограничения

Аннотация

Full Text

Selected References